| GPC Regroups
During its third-quarter conference call yesterday, GPC Biotech (Nasdaq: GPCB) gave investors an idea of what to expect down the road, now that it has to regroup in the wake of surprisingly negative study results on its lead drug. Last week, GPC announced that in a phase 3 study, its chemotherapy treatment Satraplatin failed to improve overall survival rates in late-stage prostate cancer patients, compared with a control group. The company didn't give any updates on the multiple subgroup analyses, but as GPC's CEO has said, it's now best to consider Satraplatin a phase 2 compound. Satraplatin is still a viable drug candidate, based on the data it has produced so far. But now that GPC has to push the drug through phase 2 studies and start phase 3 testing all over again, it will almost certainly take years before Satraplatin reaches the market -- if it ever gets that far at all.
TGen finds key prostate cancer gene
Scientists from TGen and other research facilities and universities have identified a gene that may be linked to an aggressive form of prostate cancer, a finding that researchers say could advance the treatment of the disease. The research eventually could yield a simple blood test to help doctors and patients determine the best course of treatment for the disease, scientists say. That would be an important step because physicians now have no way of knowing whether a prostate tumor is dangerous, prompting many unnecessary radiation treatments and surgeries that can have harmful side effects. The scientists believe the gene, called DAB2IP, aids in suppressing tumor growth. When the gene takes on a variant form, the body's natural protection is stripped away, allowing prostate cancer to spread unchecked, researchers say.
TGen team, other researchers find genetic clues to prostate cancer
Scientists from the TGen and other research facilities and universities have identified a gene that may be linked to an aggressive form of prostate cancer, a finding that researchers say may advance the treatment of the disease. The scientists believe the gene, called DAB2IP, aids in suppressing tumor growth. When the gene takes on a variant form, the body's natural protection is stripped away, allowing prostate cancer to spread more rapidly, researchers say. Scientists say the research eventually could yield a simple blood test that helps doctors and patients determine the best course of treatment for the disease. .
Clues to prostate cancer found
Scientists from the TGen and other research facilities and universities have identified a gene that may be linked to an aggressive form of prostate cancer, a finding that researchers say may advance the treatment of the disease. The scientists believe the gene, called DAB2IP, aids in suppressing tumor growth. When the gene takes on a variant form, the body's natural protection is stripped away, allowing prostate cancer to spread more rapidly, researchers say. Scientists say the research eventually could yield a simple blood test that helps doctors and patients determine the best course of treatment for the disease. .
3 of family killed in hit-and-run case
Migrants also have high incidence of sexual transmitted infections (STIs) and reproductive tract infections (RTIs), making them more vulnerable to HIV/AIDS. In the last evaluation conducted on HIV/AIDS targeted intervention projects being run to cover rickshaw-pullers and migrants from Colony no 4, the Department of Community Medicine, PGI had showed links between migration and risk to HIV/AIDS. Sharing the findings of the study with a group of development experts gathered at Parwanoo to discuss the implications of the issue today, Dr Lakshmi from the PGI said 10 to 15 per cent rickshaw-pullers and migrants inhabiting Colony number 4 had STIs and RTIs. Among rickshaw-pullers, who were surveyed during the evaluation of projects being run by the State AIDS Control Society some time ago, experts found that 3 per cent of them had pus formations in the genitalia; 10 to 12 per cent of wives of the surveyed rickshaw-pullers had the problem of pustules and ulcers.
Treviso 33 Newport Gwent Dragons 35
Sweeney missed the chance to steady the ship when his penalty drifted wide and Treviso capitalised when Alberto Sgarbi beat Mustoe with ease to score a third try for Treviso. Goosen added the conversion as well as two long-range penalties to put the home side 33-32 ahead 15 minutes from time. But Newport switched back on and Sweeney's late drop-goal was enough to secure all five points. Click here to send us your sporting feedback .
|
